Ani Pharmaceuticals Inc (ANIP) Stock Price & Analysis
Ani Pharmaceuticals Inc (ANIP) fell 1.12% to USD 77.65 as of July 25, 2026 at 20:46 UTC, according to Nexqual real-time market data.
ANIP last closed at USD 78.53; the session ranged USD 77.43–79.14 on volume of 151,042 shares. Market capitalization is $1.77B, with a 52-week range of USD 62.61–99.5 (NGM). Source: Nexqual, July 25, 2026 at 20:46 UTC.
Key Statistics (as of July 25, 2026 at 20:46 UTC)
| Price | USD 77.65 |
|---|---|
| Change | ▼ 1.12% (down) |
| Previous Close | USD 78.53 |
| Open | USD 79.04 |
| Day Range | USD 77.43 – 79.14 |
| 52-Week Range | USD 62.61 – 99.5 |
| Volume | 151,042 shares |
| Market Cap | $1.77B |
| Exchange | NGM |
Technical Analysis (ANIP)
Nexqual's technical model rates ANIP "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 20:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.27 (neutral) |
| vs SMA50 | Below (USD 81.06) |
| MACD | -1.02 (negative) |
Analyst Ratings (ANIP)
Wall Street analysts rate ANIP "Buy" based on 8 analysts, with a mean price target of USD 110 (range USD 91–124), per Nexqual as of July 25, 2026 at 20:46 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 110 |
| High Target | USD 124 |
| Low Target | USD 91 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (ANIP)
| Next Earnings Date | 2026-08-07 |
|---|---|
| EPS Estimate | USD 2.04 |
| Revenue Estimate | $260.13M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.05 vs est 1.3 ▲ beat |
| 2025-12-31 | USD 2.33 vs est 1.98 ▲ beat |
| 2025-09-30 | USD 2.04 vs est 1.77 ▲ beat |
| 2025-06-30 | USD 1.8 vs est 1.42 ▲ beat |
Source: Nexqual, July 25, 2026 at 20:46 UTC.
Financials & Fundamentals (ANIP)
| Total Revenue | $923.71M |
|---|---|
| Revenue Growth (YoY) | +20.50% |
| Gross Margin | +60.83% |
| Operating Margin | +16.30% |
| Profit Margin | +9.98% |
| ROE | +18.32% |
| Debt / Equity | 112.08 |
| Current Ratio | 3.12 |
| Total Cash | $326.06M |
| Total Debt | $630.21M |
| Free Cash Flow | $140.26M |
Source: Nexqual, July 25, 2026 at 20:46 UTC.
Financial Health Score (ANIP)
Nexqual rates Ani Pharmaceuticals Inc's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 20:46 UTC.
| Growth | Strong — Revenue +44% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 61%, operating 16% |
| Balance Sheet | Mixed — $326M cash vs $630M debt |
| Cash Flow | Strong — FCF $140M, 16% margin |
| Efficiency | Solid — ROE 18%, ROA 5.0% |
Ownership (ANIP)
| Insider Ownership | +5.53% |
|---|---|
| Institutional Ownership | +110.38% |
| Shares Outstanding | 22.73M |
| Float | 19.42M |
| Short % of Float | +18.10% |
Source: Nexqual, July 25, 2026 at 20:46 UTC.
Leadership (ANIP)
Ani Pharmaceuticals Inc is led by Nikhil Lalwani (age 47), President, CEO & Director, per Nexqual as of July 25, 2026 at 20:46 UTC.
| President, CEO & Director | Nikhil Lalwani (age 47) |
|---|---|
| Senior VP of Finance & CFO | Stephen P. Carey (age 54) |
| Senior Vice President of Generics | Ori Gutwerg (age 50) |
| Head of R & D, COO of New Jersey Operations & Director | Muthusamy Shanmugam MS R.Ph. (age 57) |
| Senior Vice President of Corporate Development & Strategy | Chad Gassert (age 49) |
Major Backers & Investors (ANIP)
Notable institutional backers of Ani Pharmaceuticals Inc include Soleus Capital Management, L.P., Tang Capital Management, LLC, Goldentree Asset Management LP, according to Nexqual as of July 25, 2026 at 20:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 3.61% |
| Tang Capital Management, LLC | 3.11% |
| Goldentree Asset Management LP | 2.94% |
| Deep Track Capital, Lp | 2.64% |
| Millennium Management | 2.6% |
| Arrowstreet Capital, Limited Partnership | 2.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.86% |
| Vanguard Group | 7.15% |
| State Street | 4.12% |
| Dimensional Fund Advisors | 2.34% |
Source: Nexqual, July 25, 2026 at 20:46 UTC.
From Ani Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA") approved the Company's Supplemental New Drug Application ("sNDA") for Cortrophin Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis ("MS") and rheumatoid arthritis ("RA"), in addition to excess urinary protein due to nephrotic syndrome.
- Any change in one of our API suppliers generally is required to be approved by the FDA through a prior approval supplement ("PAS").
- From time to time, we have experienced temporary disruptions in the supply of certain of such imported API due to FDA inspections and customs delays.
- Generally, prescription pharmaceutical products distributed in the U.S., whether branded or generic, must be approved by the FDA through the NDA, 505(b)(2) New Drug Application ("505(b)(2) NDA") or ANDA processes.
Partnerships
- In the wake of the executive orders and related executive initiatives, a number of pharmaceutical manufacturers have announced direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding pricing for drugs, including prices for Medicaid drugs and newly launched products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals, Inc. | USD 12.78 | ▼ 2.14% |
| AMPH | Amphastar Pharmaceuticals, Inc. | USD 18.72 | ▼ 3.01% |
| ANIK | Anika Therapeutics Inc. | USD 14.95 | ▼ 0.4% |
| COLL | Collegium Pharmaceutical, Inc. | USD 35.2 | ▲ 1.38% |
| PCRX | Pacira BioSciences, Inc. | USD 25.88 | ▲ 1.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:46 UTC. This page is informational and not investment advice.